Patent · US Active

RNA-editing oligonucleotides and uses thereof

US12031131B2 · kind B2 · utility

0Cited by
9References
27Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 3, 2023
Grant dateJul 9, 2024
Priority date
Expiry dateMay 3, 2043

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2310/351
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

The present disclosure features useful compositions and methods to treat disorders for which deamination of an adenosine in an mRNA produces a therapeutic result.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.